Key result
Ziprasidone treatment did not significantly alter 5-HT(1A) receptor availability, but on-medication binding correlated with negative symptom improvement (r=0.96, p=0.004).
Why the study?
Does ziprasidone alter 5-HT(1A) receptor availability in individuals with schizophrenia?
Population
6 individuals with schizophrenia
Comparison
Ziprasidone vs Medication-free baseline
Design
Cohort
Authors
Loading...
Small pre-post PET study suggests ziprasidone may alter 5-HT1A availability; leaves open its clinical relevance and requires confirmation in larger trials.
Observational (n=6)
Does ziprasidone alter 5-HT(1A) receptor availability in individuals with schizophrenia?
Ziprasidone treatment does not significantly reduce 5-HT1A binding in schizophrenia, but orbitofrontal binding correlates with improvement in negative symptoms.
Frankle et al. (2010) conducted an observational in schizophrenia (n=6). Ziprasidone vs. Medication-free (baseline) was evaluated on 5-HT(1A) availability (regional BP(P) or BP(ND)). Ziprasidone treatment did not significantly alter 5-HT(1A) receptor availability, but on-medication binding correlated with negative symptom improvement (r=0.96, p=0.004).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: